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Background: Depression and dementia are common incapacitating diseases in old age.
The exact nature of the relationship between these conditions remains unclear, and
multiple explanations have been suggested: depressive symptoms may be a risk factor
for, a prodromal symptom of, or a coincidental ﬁnding in dementia. They may even be
unrelated or only connected through common risk factors. Multiple studies so far have
provided conﬂicting results.
Objectives: To determine whether a systematic literature review can clarify the nature of
the relation between depressive symptoms and dementia.
Methods: Using the Patient/Problem/Population, Intervention, Comparator, Outcome or
PICO paradigm, a known framework for framing healthcare and evidence questions, we
formulated the question “whether depressive symptoms in cognitively intact older adults
are associated with a diagnosis of dementia later in life.” We performed a systematic
literature review of MEDLINE and PsycINFO in November 2018, looking for prospective
cohort studies examining the aforementioned question.
Results: We critically analyzed and listed 31 relevant papers out of 1,656 and grouped
them according to the main hypothesis they support: depressive symptoms as a risk
factor, not a risk factor, a prodromal symptom, both, or some speciﬁc other hypothesis. All
but three studies used clinical diagnostic criteria for dementia alone (i.e., no biomarkers or
autopsy conﬁrmation). Several studies contain solid arguments for the hypotheses they
support, yet they do not formally contradict other ﬁndings or suggested explanations and
are heterogeneous.
Conclusions: The exact nature of the relationship between depressive symptoms and
dementia in the elderly remains inconclusive, with multiple studies supporting both the risk
factor and prodromal hypotheses. Some provide arguments for common risk factors. It
seems unlikely that there is no connection at all. We conclude that at least in a signiﬁcant
part of the patients, depressive symptoms and dementia are related. This may be due to
common risk factors and/or depressive symptoms being a prodromal symptomof dementiain.org February 2020 | Volume 11 | Article 341
Wiels et al. Depression and Dementia
Frontiers in Pharmacology | www.frontiersinand/or depression being a risk factor for dementia. These causal associations possibly
overlap in some patients. Further research is warranted to develop predictive biomarkers
and to develop interventions that may attenuate the risk of “conversion” from depressive
symptoms to dementia in the elderly.Keywords: depression, dementia, cognitive decline, Alzheimer, aging, biomarkersINTRODUCTION
Rationale and Objectives
Neuropsychiatric diseases are a leading cause of disability
worldwide, with numbers expected to increase dramatically in
the coming decades, mainly due to aging populations
(Alzheimer’s Disease International, 2013). Possibly the most
incapacitating of these illnesses is dementia—causing
substantial physical and psychological disability, suffering,
dependency, and economic costs for patients, caregivers, and
society alike (Livingston et al., 2017). Several potentially disease-
modifying drug trials may have failed because a disease like
Alzheimer’s (AD) is usually diagnosed clinically after underlying
pathological processes have already been going on for years, or
even decades (Jack et al., 2010; Jansen et al., 2015; Petersen,
2018). This, in turn, has led to a major interest in possible
prodromal or (modiﬁable) risk factors for the development of
dementia (Baumgart et al., 2015). Even though most forms of
dementia are currently incurable, it has been hypothesized that a
10% reduction of known risk factors could result in a global
decrease of more than one million future cases of dementia
(Barnes and Yaffe, 2011).
Depressive symptoms have been linked to dementia. Indeed,
clinicians have long acknowledged that depression in the elderly
can mimic dementia in a situation known as depressive
pseudodementia (Alexoupoulos et al., 1993). However,
depressive symptoms may also be the ﬁrst clinical
manifestation of incipient dementia. Indeed, behavioral and
psychological symptoms, such as depression, are highly
prevalent in patients with dementia, leading to overlap in
clinical presentations of cognitive impairment in the elderly
(Savva et al., 2009). Others have suggested that depression and
dementia share common risk factors and thereby frequently
occur together without being causally linked themselves
(Enache et al., 2011), or that psychological symptoms may
occur (merely) as a reaction to incipient decline in patients
who are aware of their cognitive disturbances. Another
explication uses the “cognitive reserve” paradigm. This idea
posits that intercurrent (physical or mental) illness in an
already diseased and/or aged brain will lower the threshold for
experiencing cognitive problems and therefore cause symptoms
of the same pathophysiological process to manifest earlier (Stern
et al., 1994). Multiple studies designed to assess risk and causality
have provided conﬂicting results (Bennet and Thomas, 2014).
Depression in the elderly is more often associated with
cognitive symptoms as compared to depressive disorders of
earlier adulthood (Lam et al., 2014). On the other hand,
depression itself may actually cause cognitive decline—.org 2conceivably related to certain pathophysiological processes of,
for example, frontal and hippocampal atrophy possibly through
glutamatergic or steroid-related toxicity (Peavy et al., 2007; Byers
and Yaffe, 2011; Taylor et al., 2013). Still other studies have
pointed out that even early-life depressive episodes increase the
risk of later dementia (Dotson et al., 2010; Simões do Couto et al.,
2016). The aforementioned possibilities are, of course, not
mutually exclusive and quite possibly overlap in everyday
clinical situations.
It is clear that the association between late-life depression
and dementia is complex. To shed further light upon this
issue, we conducted this systematic literature review. It focuses
on the relationship between depressive symptoms that develop
late in life and the subsequent development of dementia
in general.
We acknowledge that depression (as in major depressive
disorder) and depressive symptoms are not interchangeable
terms. Identifying signiﬁcant depressive symptoms, rather than
limiting studies to those restricting themselves to clinician-
ascertained major depressive episode alone, however, will
broaden the scope of this review and include more large-scale
epidemiological studies. Clinicians, also, will recognize the
importance of depressive (and other neuropsychiatric)
symptoms that are not severe enough to lead to a formal
syndromal diagnosis. A similar rationale was used to examine
dementia in a broad sense. Although AD is the most common
and best studied form of dementia, vascular and mixed etiologies
will not be excluded from our review as they contribute
signiﬁcantly to the aforementioned epidemiological and clinical
problems (Alzheimer’s Disease International, 2013; Livingston et
al., 2017). Assessing the studies obtained will help identify the
gaps in our knowledge that may guide speciﬁc future research.METHODS
Research Question
To deﬁne our research question, we used the Patient/Problem/
Population, Intervention, Comparator, Outcome or PICO
paradigm—a well-acknowledged framework for framing
healthcare and evidence questions, as well as a useful tool to
develop concrete questions in complicated and multifactorial
issues such as the one we set out to examine. Through a
systematic literature review, we studied “whether depressive
symptoms (I) in cognitively intact older adults (P) are
associated with a diagnosis of dementia later in life (O),
diagnosed using validated biomarkers or criteria, as compared
to nondepressed matched controls (C).”February 2020 | Volume 11 | Article 34
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Using PRISMA as guidance (Moher et al., 2009), we included
human longitudinal, prospective cohort studies reporting on a
possible link between depression and depressive symptoms in the
elderly (older than 65 years of age) and later development of
dementia (not merely cognitive decline in a broader sense) in
statistical, and not merely narrative, terms. We did not include
case series or other designs to minimize bias, as prospective
studies are acknowledged to be less vulnerable to certain forms of
bias when ascertaining hazard and risk relationships, especially
over longer periods of time. Comparator groups were deﬁned as
matched elderly subjects without depressive symptoms. We
included memory clinic as well as general community-based
population studies of the aforementioned types. No speciﬁc
length of follow-up was required. There were no restrictions on
diagnostic criteria nor rating scales used for detection of
depression or dementia, as long as they were clearly deﬁned
and respected. We excluded studies ascertaining similar
problems in highly speciﬁc pathological situations, such as
Huntington’s disease, Down syndrome, or prion diseases. No
language or publication date restrictions were applied.
Medline and PsycINFO databases were searched in
November 2018 using combinations of the following terms we
identiﬁed through the PICO paradigm: depression (including
variant wordings such as “depressive symptoms” in MeSH),
dementia, Alzheimer, elderly, incidence, risk, hazard, cohort.
We subsequently added search terms containing clinical
diagnostic biomarkers such as magnetic resonance imaging
(MRI), positron emission tomography (PET), cerebrospinal
ﬂuid (CSF), biomarkers, amyloid, tau, and neuropsychological
test/examination (see Supplementary Material Table for these
keywords and combinations used).
We collected and deduplicated references using EndNote
software (Clarivate Analytics). Titles and abstracts were
screened by carefully excluding publications irrelevant to our
research question (mainly in vitro studies, cross-sectional
designs, papers about highly speciﬁc other illnesses as
mentioned above, case studies…—i.e., publications clearly
incompatible with our inclusion criteria and research
question). Studies with possibly relevant contents were fully
read and considered for inclusion using the aforementioned
inclusion and exclusion criteria and preparing to resolve
possible conﬂicts on study inclusion or exclusion (which did
not occur) among the three authors by consensus. We further
screened the references of these articles for missed relevant
publications. All were evaluated for possible objective errors.
No studies found through PsycINFO were unlisted in Medline
searches. As such, all (n = …) refer to references obtained from
Medline. We used the Newcastle–Ottawa Scale (NOS) for cohort
studies to assess risk of bias (obtained from ohri.ca/programs/
clinical_epidemiology/oxford.asp) in prospective cohort studies.RESULTS
Results are listed in Figure 1. Out of 1,656 search results, 1,601
titles and abstracts were excluded as clearly irrelevant. Fifty-ﬁveFrontiers in Pharmacology | www.frontiersin.org 3full articles were read and evaluated, of which 27 were excluded
according to our predeﬁned inclusion criteria. In our ﬁnal
assessment, 31 studies were included. We brieﬂy mention
seven additional publications that looked at cognitive decline
sensu lato rather than dementia and ﬁve studies that included
many patients deemed too young as per our cutoff of 65 years.
Three papers by Wilson et al. (Wilson et al., 2003; Wilson et al.,
2014; Wilson et al., 2016) described similar cohorts and
neuropathological data and were merged into one additional
reference. One additional study was added through follow-up for
publication of an earlier abstract of interest the authors read at a
conference (Ezzati et al., 2019). Two other papers were included
from paper references. No data were extracted as we considered
the obtained papers to be too heterogeneous to perform
meta-analysis.
We grouped these references in ﬁve categories for review
purposes—noting that their main conclusions are not mutually
exclusive and many authors, indeed, suggest multiple
explanations for their ﬁndings. Critical assessment of the
papers’ numerical results as well as their authors’ main
interpretation thereof in the respective discussion sections was
used to classify the references in our different categories, as
discussed further in this section. Additional substantiation is
provided in the Supplementary Material.
A. Studies suggesting that depression is a risk factor for
dementia A1 (n = 7) and studies suggesting that depression
is not a risk factor for dementia or that they are linked
without reaching statistical signiﬁcance A2 (n = 8)
B. Studies that suggest that depression is an early symptom or
prodrome of dementia (n = 10)
C. Studies that suggest that depression is both an early symptom
and a risk factor (n = 1)
D. Studies demonstrating an association between depression
and dementia, without clear conclusions concerning
potential causality [n = 3 (one reference for three related
papers)]
Results are listed by their aforementioned category in
Tables 1–4 (listing A1, A2, B, C&D).
Bias assessment using the NOS did not show any systematic
difference in biases between categories, with all studies scoring
relatively high on this design quality scale. We therefore
conclude this had little inﬂuence on our ﬁndings. Results and
additional comments are available in the Supplementary
Material Table.
These studies propose that depressive symptoms confer an
additional risk of a future development of dementia in
cognitively healthy elderly individuals. This view has to be
contrasted with the hypothesis that psychological symptoms
simply accentuate or temporarily cause cognitive deﬁcits,
thereby accounting for that proportion of mild cognitive
impairment (MCI) patients who do not “convert” to dementia
but rather recover a normal cognitive status (Langa and Levine,
2014). Some studies (Irie et al., 2008; Ezzati et al., 2019) indeed
corrected for baseline emotional and cognitive scores to address
this possibility. We did not include studies evaluating the linkFebruary 2020 | Volume 11 | Article 34
Wiels et al. Depression and Dementiabetween early-life (onset before 65 years of age) depression and
later dementia, even though this could be of interest to our
research question; indeed, other review efforts appear to suggest
this link (Ownby et al., 2006). Interestingly, several studies,
including the largest one (Burke et al., 2016) in this category,
suggest that dementia risk in people with depressive symptoms
increases further when corrected for classically biasing factors
such as age, education, or socioeconomic status, thus providing
an argument against the position that depressive symptoms and
dementia are linked solely through common risk factors and
justifying classiﬁcation in category A1. This relation becomes
even stronger when associated with certain APOE genotypes, a
well-known genetic risk factor for AD—a ﬁnding also reported
by smaller samples (Irie et al., 2008; Kim et al., 2010).
Considering some of the proposed pathophysiological
mechanisms (chronic inﬂammation, glucocorticoid toxicity,
neuronal energetic dysregulation, etc.), a true biological risk
relationship would imply that more severe and/or long-
standing depression increases one’s chance of cognitive
deterioration due to a neurodegenerative or cerebrovascular
brain disease. Although some reports (Wilson et al., 2003; Gatz
et al., 2005; Saczynski et al., 2010; Langa and Levine, 2014) have
shown such a link, most studies use depressive symptoms as a
binary value (depressed–not depressed) and/or contain too many
individuals with mild depressive symptoms to really establish a
“dose–response” relationship of this kind. Furthermore, most
studies did not evaluate these proposed mechanisms (e.g.,
through blood or CSF analysis, functional or advancedFrontiers in Pharmacology | www.frontiersin.org 4imaging). It is etiologically difﬁcult to disentangle depression
being a pure risk factor or an actual prodromal symptom of
dementia, especially during the 2- or 3-year follow-up of most
studies. However, some studies followed patients for up to 17
years and reported similar ﬁndings (Saczynski et al., 2010). One
strong argument for the true risk hypothesis would be clinical
trials indicating that successful treatment of major depressive
episodes lowers the incidence of (solidly diagnosed) degenerative
dementia. This is a controversial question, with multiple studies
of different (mainly pharmacological) treatments providing
conﬂicting results (Lee et al., 2016; Jacob et al., 2017; Almeida
et al., 2017; Chu et al., 2018; Brauer et al., 2019). We further note
that the successful treatment of clinical depression is a challenge
in itself, as only one in three patients respond to ﬁrst-line
treatments and as many remain treatment resistant after
multiple treatments, a situation that may be even more
frequent in the elderly (Rush et al., 2006). Interestingly, some
authors have even suggested that anti-amyloid therapies may
have a role to play in treating late-life depressive syndromes
(Mahgoub and Alexopoulos, 2016). Nevertheless, the studies we
examined here fail to provide us with any additional evidence of
this sort.
These studies did not ﬁnd an increased risk of dementia in
case of late-life depressive symptoms, as opposed to the ﬁrst
group of studies. The authors’ point is generally based upon an
absence of signiﬁcant ﬁndings or results that lose statistical
signiﬁcance after correction for certain biasing factors. Some,
however, do establish a risk relationship in speciﬁc situations,FIGURE 1 | Selection of studies included in this systematic review.February 2020 | Volume 11 | Article 34
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2002; Kim et al., 2010). Others report an association with
depressive episodes earlier in life as opposed to current
symptoms (Pálsson et al., 1999; Geerlings et al., 2008). Several
studied rather small populations, and their relatively low
numbers of incident dementia cases may in itself account for a
negative result (Geerlings et al., 2008; Becker et al., 2009; Blasko
et al., 2010; Kim et al., 2010). This may also be the case for wide
conﬁdence intervals [e.g., in Geerlings et al. (2008), 0.82–6.69].
Some of these did not ﬁnd any signiﬁcant risk factors for
dementia, apart from increasing age, which stands in apparent
conﬂict with what is generally accepted in dementia research
(Baumgart et al., 2015; Livingston et al., 2017) and quite possibly
suggests insufﬁcient power. We note that one study (Kim et al.,
2010) reported an increased risk of dementia only for depressive
males carrying an APOE ϵ4 allele. Lindsay et al. (Lindsay et al.,
2002) looked only at syndromal (i.e., clinician-diagnosed)
depression, as opposed to most of the other studies that
utilized (self-reported) symptom scores. Two studies (41 andFrontiers in Pharmacology | www.frontiersin.org 544) report on the same cohort. The population studied in
(Geerlings et al., 2008) was analyzed again in (Mirza et al.,
2016), which is category B and supports the prodrome
hypothesis (Table 3). Most population sizes in Table 2 are
smaller than those in other groups. In combination with other
factors, as mentioned above, we conclude that several of these
studies were probably underpowered to detect a connection and
do not formally nor decisively contradict the notion that
depressive symptoms and dementia are connected.
Considering that both neuropsychiatric illnesses may
manifest themselves epidemiologically as hazard increasing, it
can be difﬁcult to distinguish between a causal risk factor and
prodromal symptom in the years leading up to a diagnosis of
dementia—as discussed above. Nevertheless, the authors in this
category found support in their ﬁndings for the latter hypothesis.
Several arguments in favor of this position are advanced by the
authors of these studies. These include an increasing symptom
burden over time (Mirza et al., 2016) and no effect of (the length
of) episodes occurring earlier in life as opposed to current andTABLE 1 | (Category A1): Studies suggesting that depression is a signiﬁcant risk factor for dementia.
Study Cohort N Mean
age
(SD)
%
Female
FU Depression
assessment
Diagnostic
criteria of
cognitive
decline
Incidence of
dementia
Risk? Risk adjustments
(Brodaty
et al.,
2012)
Community of
English
speaking
Australians
799 (480
NC, 319
MCI). 169
drop-outs
78
(4.7)
67.8% 2 years NPI Petersen
MCI, DSM-
IV Dementia
11 from MCI, 3
from NCI, too
small for
subtyping
OR 3.67 [1.1–
12.5]
No difference (age,
sex, education, NPI
score)
(Burke
et al.,
2016)
Prospective
UDS NACC:
80% White,
13% African,
6% Hispanic
11453 start,
8762 more
than 1 visit
71
(10.89)
65.2% Mean 3
years (1-10)
1) Recent 2)
Earlier 3)
Current
episode
(DSM-IV)
AD
NINCDS/
ADRDA
330 AD.
Subgroups not
clearly reported
1) HR 2.35
[1.88–2.94] 2)
HR 1.35 [1.06–
1.73] 3) HR 2.82
[2.21–3.59]
Stronger after
correction 1) HR 5.75
[3.28–10.07] 2) 3.20
[1.78–5.73] 3) HR
5.50 [3.09–9.64]
(Devanand
et al.,
1996)
Community in
Manhattan
30% White,
41% Latino
27% African
852 NC at
baseline,
478 one or
more FU
sessions
73
(7.1)
69.4% 1-5, mean
2.54 years
(1.12 SD)
HAM-D >10
and ‘mood’
item
DSM-III-R 61 cases, (21%
depressed vs
9% non), mostly
AD (2 other, 1
PSP)
RR 2.94 [1.7-
4.9]
Still signiﬁcant (RR
2.05) after age,
education, Moderate
CI
(Ezzati
et al.,
2019)
Einstein Aging
study: Bronx
community,
65% white
1219 78
(5.4)
70+
62% Yearly visits
for 4.5
years (3.5
SD) up to
17 years
GDS-15 DSM-IV 132 cases, 111
AD
Per point HR
1.11 [1.03-1.19],
not signiﬁcant
before 3 years
Age, sex, race,
education,
comorbidity and
baseline cognition
(BIMC)
(Irie et al.,
2008)
USA Japanese
in Hawaii
1932 76
(3.6)
0% 6.1 years
mean
CES-D > 9 DSM-III-R,
NINCDS/
ADRDA
6.3% (e4), 9.3%
(dep) 13.7%
(both) 4.2%
(neither)
Dementia HR
2.2 [1.3–3.7] AD
2.9 [1.4–5.9]
Classic risk factors
and self-reported
memory
(Saczynski
et al.,
2010)
Framingham
study:
prospective
community
cohort
949 79 (5) 63.6% Mean 8, up
to 17 years
CES-D > 16 DSM-IV,
CDR >1,
NINCDS/
ADRDA
164 cases (136
AD)
Dementia HR
1.72 [1.04–2.84]
AD 1.76 [1.03–
3.01]
Age, education,
homocysteine, APOE,
MCI
(Spira
et al.,
2012)
Oldest old
white (SOF
WISE)
302 87 (2)
> 85
100% 5 years
after
baseline
GDS-15 > 6 Petersen
MCI, DSM-
IV-TR
dementia
84 cases 65%
of GDS ≥6 &
37% < 6
MOR 3.15,
[1.03-9.65]
Risk factors, alcohol,
benzodiazepinesFebruary 2020 |Values in square brackets are 95% conﬁdence intervals. p-values are under 0.05 unless otherwise speciﬁed. UDS-NACC, Uniform Data Set - National Alzheimer’s Coordinating Centre;
NC, Normal cognition; MCI, Mild Cognitive Impairment; SD, Standard Deviation; GDS, Geriatric Depression Scale; HAM-D, Hamilton Depression Rating Scale; NPI, Neuropsychiatric
Inventory; DSM, Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association); FU, follow-up, NINCDS; National Institute of Neurological and Communication
Disorders and Stroke; ADRDA, Alzheimer’s Disease and Related Disorders Association criteria; CES-D, Centre for Epidemiological Studies Depression scale; BIMC, Blessed Information
Memory Concentration; CDR, Clinical Dementia Rating Scale; SOF-WISE, Study of Osteoporotic Fractures - Women; Cognitive Impairment Study of Exceptional Aging.Volume 11 | Article 34
Wiels et al. Depression and Dementiarecent symptoms (Fuhrer et al., 2003; Li et al., 2011). Others note
a clear temporal relationship of both illnesses around diagnosis
(Lenoir et al., 2011; Almeida et al., 2017) or a synergistic effect
with white matter pathology (Verdelho et al., 2013). Concerning
this last element especially, it is posited that in some proportion
of elderly patients, depressive symptoms actually represent the
organic effect of ongoing pathological processes (cerebrovascular
and/or neurodegenerative) on affect-modulating networks in the
brain (Thomas et al., 2002).
One must also consider here the possibility that depressive
symptoms could be a reaction to patients’ awareness of cognitive
decline and thereby frequently manifest during prodromal and
early stages of dementia. Several authors, however, reported no
clear effect of baseline cognition and emotional symptoms to later
dementia (Chen et al., 1999; Geerlings et al., 2000; Fuhrer et al.,
2003; Irie et al., 2008; Li et al., 2011; Mirza et al., 2016; Ezzati et al.,
2019), providing a solid argument against this position.
Furthermore, other studies have reported that no clear or
ubiquitously negative reaction to dementia in recently diagnosed
subjects can be demonstrated (Carpenter et al., 2008). We
therefore hypothesize that, even though this may occur in
everyday clinical situations (e.g., someone worrying about future
cognitive decline, possibly due to contact with the dementing
illness of a relative), a negative affective response to noticing one’sFrontiers in Pharmacology | www.frontiersin.org 6own decline alone cannot explain the association between
depressive symptoms and dementia in all patients. Future and
ongoing studies like the ABIDE project (van Maurik et al., 2019)
will be of help to shed further light upon this association.
These studies propose multiple explanations or more complex
associations between depression and dementia. Ganguli et al.
(2006) (studying the same cohort as Chen et al. (1999) in category
B, Table 3) hypothesized that, while depressive symptoms are
indeed cross-sectionally associated with cognitive symptoms, they
were unrelated to later cognitive decline, while noting that
increasing cognitive symptoms associated with depression likely
represent incipient dementia. Kaup et al. (Kaup et al., 2016)
described that increasing severity of depressive symptoms on
repeated assessments, rather than a one-time scoring, was
associated with increased risk of dementia, thereby lending
support to both risk factor and prodromal hypotheses. Luppa
et al. (2013), through multiple interaction models, show that only
major depressive episodes (i.e., depression in the strict sense)
seem to increase risk of dementia as opposed to milder depressive
symptoms whose effect disappears in multivariate analyses.
Wilson et al. (2003; 2014; 2016) have published three
interesting studies. Their 2003 paper showed that, in a group
of 130 elderly religious order members, each increase
in depressive symptomatology increased the risk of beingTABLE 2 | (Category A2): Studies not suggesting that depression is a signiﬁcant risk factor for dementia.
Study Cohort N Mean age
(SD)
% Female FU Depression
assessment
Diagnostic
criteria of
cognitive
decline
Incidence of
dementia
Risk? Adjustments
(Becker
et al.,
2009)
CHS-CS
Pittsburgh
community
288 78 (3.65) 63% 7.1
years
(1–9)
CES-D >10 3MSE, DSM-
IV, NINCDS/
ADRDA
48, all AD None found All kinds of risk
factors in CHS
study
(Blasko
et al.,
2010)
VITA – 2
Vienna districts
331 never
depressed
undemented
76 (0.5) 56.5% 0 – 2.5
– 5
years
DSM-IV, sGDS NINCDS/
ADRDA
33 Serum Ab42,
male gender,
age were risks
Multivariate
logistic
regression
analyses
(Geerlings
et al.,
2008)
Rotterdam
population
Scan Study
486 74 (6.5) 49% 5.9
years
(1.5
SD)
Interview-based
(early vs. late
(60y)) CES-D
16
CAMDEX and
standard
criteria
33 AD EARLY history
of depression
risk factor
MRI volumetrics
and WML
(Kim et al.,
2010)
Korean
community
survey
518 72 (5) 65+ 54.4% 2.4
years
Korean GDS Standard
criteria
45 (34 AD, 7
VaD, 4 other)
Strong risk of
dep + APOE
men (cf. Irie)
Vascular risk
factors, APOE
(Lindsay
et al.,
2002)
Prospective
Canadian
Health & Aging
study
4609 Cases 87
Controls
78 (70–
100)
58% 5 years
after
initial
visit
DSM-III-R (no
symptoms
only)!
NINCDS-
ADRDA, DSM-
III, NINDS-
AIDEN
194 AD, 527
MCI and
‘other’
dementias
Age,
education,
APOE
Reduction by
wine, coffee,
NSAIDs,
exercise,…
(Mossaheb
et al.,
2012)
VITA – 2
Vienna districts
437 (296 at
60 months)
never
depressed
76 (0.5) 55% 60
months
DSM-IV-TR
questionnaire,
HDRS, sGDS
NINCDS-
ADRDA
65 (AD) OR 5.27 [1.62-
17.2] for loss
of interest only
Risk factors,
biochemical
parameters,
APOE
(Pálsson
et al.,
1999)
Gothenburg
census of 85
year olds
227 healthy
and 62
depressed
85 years
old at
baseline
Not
explicitly
stated in
subgroups
3 years DSM-III-R,
history and
records
Not clearly
stated, MMSE
50 cases Only early
onset MDD
CT volumetrics
(Vinkers
et al.,
2004)
Leiden (NL) 85
year olds
500 (298 4th
year)
85 years
old at
baseline
63% Yearly
for 4
years
GDS-15 MMSE,
Stroop, LDCT,
12 Word
Recall
Not explicitly
stated
Correlation but
no risk of
decline
Mixed modelsFebruary 2020 | Volum3MSE, Modiﬁed Mini Mental State Examination; WML, White Matter Lesions; AIDEN, Association Internationale pour la Recherche et l’Enseignement en Neurosciences; MDD, Major
Depressive Disorder; LDCT, Letter Digit Coding Test.e 11 | Article 34
Wiels et al. Depression and Dementiadiagnosed with AD. However, this did not seem to correlate well
with the burden of AD neuropathology at autopsy, leading the
authors to conclude that some other mechanism must drive the
association between depression and dementia. They conﬁrmed
this ﬁnding in an expanded cohort of 1,750 people, 600 of whom
underwent neuropathological examination, and again in a third
paper. They found no support for depression being merely a
psychological reaction to incipient cognitive decline but
conﬁrmed the association between depressive symptomatology
and later dementia. They hypothesized that some mechanism,
independent of the postmortem hallmarks of AD (i.e., plaques
and tangles), must drive the association between depression and
cognitive decline. Exactly what drives this intriguing ﬁnding
remains to be elucidated in future studies. These should include
newer biomarkers, as guided by fundamental scientiﬁc insights.
An amyloid-PET-based study has yielded similar results (i.e.,
showing no clear link with amyloid pathology) when evaluatingFrontiers in Pharmacology | www.frontiersin.org 7hippocampal atrophy in a cohort of depressed people and matched
controls (De Winter et al., 2017), even though others have pointed
out that amyloid-positive individuals do have a tendency to
progressively manifest more neuropsychiatric symptoms
(Harrington et al., 2017; Donovan et al., 2018). It is clear that
further research efforts could and should use the newer antemortem
diagnostic techniques (e.g., LP and/or PET) to add to these ﬁndings.DISCUSSION
Our systematic literature review yielded no conclusive arguments
in support of or contradicting the exact nature of the etiological
relationship between depression and dementia. Multiple studies,
however, contain convincing arguments for the respective
position on this topic (A1, A2, B, C, D) that their authors
defend. Some issues raised in the Results section of categoryTABLE 3 | (Category B): Studies suggesting that depression is a prodromal symptom of dementia.
Study Cohort N Mean
age
(SD)
%
Female
FU Depression
assessment
Criteria for
cognitive
decline
Incidence Risk? Adjustments
(Almeida
et al.,
2017)
Health in
Men
(Western
Australia)
4922 77
(3.7)
71-89
0% 8.9 mean,
up to 14
years
sGDS-15, history,
health record
Healthcare
records coding
903 cases
(18%)
aSHR: Ever 1.3
[1.2-1.7] Past 1.3
[1.0-1.6] Current
1.5 [1.2-2.0]
Antidepressant use,
stroke, risk factors.
ONLY in the ﬁrst 5
years
(Chen
et al.,
1999)
MoVIES
cohort USA
97% white
954 65-85 54.6% 8 years
with 2
yearly
intervals
mCES-D NINCDS-
ADRDA, DSM-
III, CERAD
78 (61 AD) ‘Reverse’ risk Age, sex,
education, self-
reported cogn.
(Fuhrer
et al.,
2003)
Aquitaine
France
community
3777
(1500
at year
8)
75 (7)
65+
58.3% 8 years (1,
3, 5, 8)
CES-D (men 17
women 23)!
NINCDS-
ADRDA, DSM-
III-R, Hachinski
280 cases
(200 AD)
OR men 3.5 [1.9–
6.5] Women [1.2
0.7–2.0]
Hypertension in
men 50% additional
risk
(Gatz et
al., 2005)
Manitoba
Canada
Community
766 75 (6)
65+
61.7% 5 years CES-D (> 16 and
other values)
Standard
Criteria
56 (36 AD) AD OR 2.75 [1.04–
7.24] Dementia
2.37 [1.02–5.54)
Not earlier reported
depression, not
duration of
symptoms
(Geerlings
et al.,
2000)
Two
Netherlands
cohorts
1911
+
1894
73 (5)
and
70 (8)
62.3%
and
52.9%
4 years GMSS and CES-D
respectively
“3 point MMSE
drop” and
criteria
53 AD
AMSTEL
aOR >8y educated
5.3 [1.8-15]
Age, gender,
education,
psychiatric
(Lenoir
et al.,
2011)
Three
French Cities
(3C Study)
7989 74 (5)
65+
61% 2 times 2
years
MDE-MINI (DSM
IV), CES-D
NINCDS-
ADRDA, DSM-
IV, Hachinski,
AIREN
180 AD, 24
Vasc Dem,
29 mixed, 43
various
Dementia HR 1.5
[1.2–2.2] Vascular
4.8 [2.2–10.7
Risk factors and
age, MRI WML, not
earlier episodes
(Li et al.,
2011)
Seattle ACT
study
3410 75 (6)
65+
60% 7.1
average,
Biennially
up to 15
years
CES-D-11, history
of past episodes
CASI, DSM-IV,
NINCDS-
ADRDA
658: 386 AD,
89 Vasc, 113
mix, 70 other
All cause aHR 1.61
[1.29- 2.01]
Age, gender,
education, baseline
CASI
(Mirza
et al.,
2016)
Rotterdam
community
scan study
3325 74.88
(IQR
71–
80)
60% 3 times in
10 years
CES-D, HADS-D –
3 trajectories!
MMSE, GMS,
CAMDEX, DSM-
III-R, NINCDS-
ADRDA
434 dementia
– 348 AD, 26
Vasc, 60
other
Increasing trajectory
dementia HR 1.42
[1·05–1·94]
Age, sex, APOE,
education,
medication, risk
factors, cognition
(Palmer
et al.,
2007)
Stockholm
community-
based
185
(+47
MCI)
84 (5)
75-95
years
84.9% 3.4 years
(0.6 SD)
Comprehensive
Psychopathological
Rating Scale
DSM-III-R,
NINCDS-
ADRDA
10 AD 7
dementia in
healthy
AD RR 1.9 [1.0-3.6]
per mood symptom
Corrected for age,
sex, education.
Anxiety in MCI
(Verdelho
et al.,
2013)
LADIS study
of WML
(clinic ﬁnding
based)
639 74.1
+- 5y
55% 3 times
annually
sGDS NINCDS-
ADRDA/AIREN
34 AD, 54
VD, 2 FTLD
GDS HR 2.4 [1.4
3.99]
Risk factors.
Previous depression
not signiﬁcantFebruary 2020 | VoaSHR, Adjusted sub-hazard ratio; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; GMSS, Geriatric Mental State Schedule; MDE-MINI, Major Depressive Disorder part
of the Mini International Neuropsychiatric Interview; CASI, Cognitive Abilities Screening Instrument; IQR, Interquartile Range; WML, White Matter Lesions.lume 11 | Article 34
Wiels et al. Depression and DementiaA2 (“not a risk factor”), however, cast doubt on the power several
of these studies to detect connections (or their absence). We
deem it unlikely that there should be no connection at all, or that
everything can be explained by subjects’ emotional responses to
incipient decline. We therefore conclude that depressive
symptoms may be both a risk factor for and a prodromal
symptom to dementia. They may sometimes be coincidental
and/or stem from shared risk factors in the elderly. Exactly what
mechanism(s) drive(s) this pathophysiological association
remain(s) unclear and could not be elucidated by this
systematic review. Limitations of our effort in this sense will be
discussed in the next section of this article.
Multiple studies were excluded from our main results as they
examined the relationship between depressive symptoms and
cognitive decline, variously deﬁned (Dufouil et al., 1996; Bassuk
et al., 1998; Yaffe et al., 1999; Wilson et al., 2004; Barnes et al.,
2006; Geda et al., 2014; Ritchie et al., 2016). Due to this
heterogeneous construct (rather than the binary dementia–no
dementia), these studies did not answer our research question.
They remain, however, certainly of interest of the broader
research area we considered in the Introduction section. Since
these studies contain useful information for investigators looking
into the cognitive effects of depression, they are listed here for
further reading. Five of them report an increased risk of cognitive
decline among depressed elders (Yaffe et al., 1999; Wilson et al.,
2004; Barnes et al., 2006; Geda et al., 2014; Ritchie et al., 2016),
whereas two of them do not (Dufouil et al., 1996; Bassuk
et al., 1998).
As we wanted to study the interaction between late-life
depression and dementia, studies including a large proportion of
subjects younger than 65 years of age were excluded. Indeed,
dementia is rare in this age group, and early- versus late-onset
depression may differ clinically (Hall and Reynolds-Iii, 2014). As
mentioned before (Ownby et al., 2006), some of these studies
suggest that [severe (Simões do Couto et al., 2016)] early-life
depressive episodes appear to have an “additive” effect onFrontiers in Pharmacology | www.frontiersin.org 8dementia risk, supporting depression as a causal factor or related
to the same underlying pathology, such as vascular disease (Van
Uden et al., 2016). Dal Forno et al. (2015) and Köhler et al. (2011)
reported similar ﬁndings, albeit in older populations. These
ﬁndings may be relevant to our review question and often imply
a causal role for depression and depressive symptoms, much like
the studies in Table 1. Even though the studies mentioned cannot
be included in our systematic review, given our inclusion criteria,
we brieﬂy refer to these studies here (Dotson et al., 2010; Köhler et
al., 2011; Dal Forno et al., 2015; Simões do Couto et al., 2016; Van
Uden et al., 2016), as most do appear to support a link between
depressive symptoms and dementia.
Neuropsychiatric symptoms in the elderly are common,
pervasive, and incapacitating. In the search for validated
biomarkers of (later) dementia, simple and cheap interventions,
such as a structured mental health assessment or a quick screening
tool for depressive symptoms, may complement expensive and/or
invasive tools like imaging and laboratory tests in determining
individual patients’ risk proﬁle. Hopefully, these can in turn lead to
tailored risk mitigation strategies for individuals at risk that can be
implemented on a large scale. Future research should aim at
identifying novel techniques that are able to identify those
depressed elders at high risk for “conversion” to dementia. There
may be a role to play in unraveling this connection for certain
issues raised in the papers we discussed. The effects of gender,
genetics, cerebrovascular disease and inﬂammation, upon the
interaction between depressive symptoms and (certain types of)
dementia should be studied further using a combination of large
datasets and modern technology. We believe that these areas of
study may yield clues to understand the actual pathophysiological
mechanisms driving the association between mood symptoms and
cognitive decline and in turn guide future trials.
We hypothesize that newer diagnostic techniques—in vivo
biomarkers through CSF analysis, targeted molecular imaging
through positron emission tomography techniques, advanced
(magnetic resonance) imaging analysis—unavailable duringTABLE 4 | (Categories C & D): Studies suggesting both or neither.
Study Cohort N Mean
age (SD)
%
Female
FU Depression
assessment
Diagnostic cri-
teria of cogni-
tive decline
Incidence Risk? Adjustments
(Ganguli et al., 2006) MoVIESBlue-
collar rural
U.S.A
1265 75 (5) 60.8% Biannually
for 12
years
mCES-D CERAD, DSM-
III-R
171 cases of
dementia
Multiple interaction
models ﬁnding no
long-term
association
Classic risk
factors
(Kaup et al., 2016) HABC
Study, mixed
USA
2488 74 (2.4) 53% 4 years CES-D-10
and
‘trajectories’
Records,
medication,
MMS decline
353 cases of
dementia
High and increasing
trajectory
Demographic
and health
factors,
cognition
(Luppa et al., 2013) LEILA 75+
Study
1265 75 years
and older,
mean 81
73% Every 1.5
years over
8 years
CES-D SIDAM - DSM
IV
183 cases of
dementia
Only for MD in
multivariate
Classic risk
factors
(Wilson et al., 2003;
Wilson et al., 2014;
Wilson et al., 2016)
Different
prospective
cohorts
130/
1750/
1965
76 (7.5) in
3rd study
73.8% Differing
per
cohort/
paper
CES-D DSM-III,
NINCDS-
ADRDA,
Pathological
criteria
346 cases of
dementia in
largest cohort
Cfr. text discussion. Cfr. text
discussion.February 2020 | VolumeSIDAM, Structured Interview for Diagnosis of Dementia of Alzheimer type, Multiinfarct Dementia and Dementia of other Aetiology; MD, Major Depression.11 | Article 34
Wiels et al. Depression and Dementiamany of the prospective study periods of the cohort studies we
cited—may facilitate in this effort in overcoming the shortcomings
of existing studies. The studies we included are mainly based on
cohorts from years or even decades ago, when much fewer (para)
clinical diagnostic tools were available. By increasing diagnostic
accuracy and concordance with pathological diagnoses, disease-
speciﬁc mechanisms may be identiﬁed more easily as compared to
the more heterogeneous cohorts described above.We theorize that
these techniques may facilitate an early identiﬁcation of those
depressed elders at an especially high risk of developing
degenerative dementia. Second, future trials should examine
whether and which treatments in the depressive elderly—with or
without evidence of preclinical or prodromal neurodegeneration—
may mitigate their risk of later dementia.LIMITATIONS AND HETEROGENEITY
-Of the Studies Included
It is technically and ethically impossible to conduct a
randomized, controlled trial to study the association between
depression and dementia. Therefore, conclusions are based on
observational studies. This means that the highest levels of
evidence quality are not met. This is especially relevant when
taking heterogeneity across studies into account in conducting
systematic reviews and meta-analyses. We note that most studies
are of similar quality when assessed using the NOS (see
Supplementary Material). We therefore deem it unlikely that
speciﬁc types of systematic bias in study design (apart from
some concerns raised over the “negative” studies in Category A2)
have inﬂuenced the categorization of studies and/or our
general conclusions.
Related to the Diagnosis of Dementia
Dementia diagnoses were based on Diagnostic and Statistical
Manual of Mental Disorders (DSM) (be it III or IV, revised or
not) criteria in all but two studies (Kaup et al., 2016; Almeida
et al., 2017), which relied on healthcare records and coding,
prescription of cholinesterase inhibitors, and other “indirect”
signs of a dementia diagnosis in their cohorts. AD diagnosis—if
evaluated separately—was similarly based on National Institute
of Neurological and Communicative Disorders and Stroke and
the Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria in most studies. Of note, almost
no studies included additional “objective” biomarkers of AD or
other dementias, which added to the heterogeneity of the
investigated populations. The relatively low etiological
diagnostic accuracy of non-biomarker-based clinical diagnostic
criteria alone does not help this issue (Elahi and Miller, 2017). A
minority of studies employed DNA analysis—mainly for APOE
genotyping (Lindsay et al., 2002; Irie et al., 2008; Kim et al., 2010;
Saczynski et al., 2010; Mossaheb et al., 2012; Mirza et al., 2016).
While most criteria for “dementia” as such are quite clear, there
are of course multiple causes for this clinical syndrome, and
several studies do not formally differentiate between AD and
other causes of dementia, very probably contributing to less clearFrontiers in Pharmacology | www.frontiersin.org 9results and precluding conclusions about speciﬁc types of
dementia and their possible association with depressive
symptoms. These issues may have inﬂuenced study ﬁndings
and the conclusions of this systematic review.
Depression Measures
It is of interest to researchers and clinicians to differentiate
between several elements of the depressive syndrome
(anhedonia, low positive affect, motivational symptoms,
vegetative or melancholic symptoms,…) to elucidate the role
they have in causing clinical overlap between multiple disease
states in the elderly: medical illness and pharmacological effects,
major depression, apathy, incipient dementia, etc. (Hall and
Reynolds-Iii, 2014). Rating scales differ in their focus on/
attributing points to these elements of the depressive syndrome.
Fourteen studies used the Centre for Epidemiological Studies–
Depression (CES-D) self-rating scale for assessing depressive
symptoms at a given moment. Nevertheless, even they differ in
the cutoff values used (e.g., 16, 11, 10, or 9 points); two studies use
a modiﬁed scale, some use different cutoff values for men and
women, while others did not. No less than nine other scales and
evaluations were used, with or without a “regular” clinical
psychiatric assessment of depression (generally based on DSM
criteria). Ascertaining past episodes of depression was even
harder due to recall bias and a general lack of recognition of
multiple depressive symptoms and episodes in the general
population (Patten, 2003). Although some of the included
studies examined speciﬁc symptom trajectories of depression,
most use a one-time screening tool inquiring about symptoms in
the last few days or weeks, which is probably inadequate to
distinguish true depression from subsyndromal depressive
symptoms. This limits strong conclusions about what kind
and/or severity of depressive symptoms are speciﬁcally related
to future dementia and should, therefore, be actively identiﬁed
and/or treated by clinicians.
Populations
Studied populations were relatively heterogeneous across cohorts.
Participants’ age was similar in most studies, with some studies
focusing on the oldest old (Pálsson et al., 1999; Vinkers et al.,
2004; Palmer et al., 2007). While a general female preponderance
in studies of the elderly is to be expected and was indeed seen in
most studies, some (29 and 47) looked at men only, with one
(Spira et al., 2012) having an all-women cohort. Most (if not all)
of these studies were conducted in the industrialized world. They
do, however, contain populations from different continents and
multiple ethnic backgrounds in rural as well as urban cohorts.
Whether study ﬁndings can be extrapolated on a cross-cultural or
global scale remains an open question.
Risk Analysis and Prospective Studies
While almost all studies corrected their results (concerning risk
of developing dementia) for potentially confounding variables,
almost none used an exactly identical list of confounders. Given
that depressive symptoms and dementia are both common and
have overlapping risk factors (e.g., socioeconomic status),February 2020 | Volume 11 | Article 34
Wiels et al. Depression and Dementiathis lack of uniformity across studies further hampers the
disentanglement of causal relationships.
As in all epidemiological studies, and especially those in old
age, attrition bias (due to loss of follow-up, intercurrent illness, or
death) is signiﬁcant. Furthermore, multiple authors have suggested
that dropped-out participants are more likely to suffer from
depression and/or dementia (Brayne et al., 1999), possibly
attenuating the risk found in study “survivors.” Moreover,
several authors have pointed out that people with depressive
symptoms have more comorbid medical illnesses and die earlier
(which is also true for people with dementia) (Almeida et al.,
2010). We hypothesize that this attrition bias may underestimate
some risk relationships and could produce false-negative results.
-Limitations of This Review
As can be expected from examining the complex association
between depressive symptoms and dementia, major
methodological differences exist between studies. There are
profound and signiﬁcant differences concerning the populations
studied, diagnostic evaluations used, follow-up frequency and
duration, corrections for bias, etc. These inconsistencies add to
the difﬁculty of answering our research question (i.e., depression
being a cause, effect, both, neither,… of dementia) that is in itself
challenging to answer using prospective studies. Grouping studies
and data that are this heterogeneous are a major limitation of the
existing data. This also complicates hypothetical statistical analyses
of data extracted from these studies.
We do not provide here a complete list of excluded studies,
did not do the initial searches in duplicate, and cannot exclude
any human errors in selection. Since the link between depression
and dementia is a hotly debated one, with publications
supporting multiple causal hypotheses, we do not think that
(positive) publication bias has a major impact on our ﬁndings,
although we cannot formally exclude this. We did not search all
of the available literature databases, although it is unlikely they
should have yielded important studies unlisted in Medline (as
illustrated by our lack of additional ﬁndings in PsycINFO).CONCLUSIONS AND FUTURE
PERSPECTIVES
Despite our clear initial research question, this systematic review
did not provide a single answer to the question of how depressive
symptoms and later dementia are related. According to our review
effort, grouping multiple large studies that provide conﬂicting
results, it remains unclear whether depressive symptoms in the
elderly are a risk factor for or a prodromal symptom of dementia.
They still may be related mainly through common causal factors,
e.g., aging or vascular disease. It seems unlikely that they are not at
all related, or only in an indirect way–for example, evidence does
not support the hypothesis that a negative emotional response to
incipient cognitive symptoms alone can explain the connection
between depressive symptoms and dementia.
Several interesting issues raised in some of the studies included,
although outside the scope of this review, also deserve furtherFrontiers in Pharmacology | www.frontiersin.org 10evaluation. These include but are not limited to the role of gender
and genetic factors, systemic inﬂammation and cerebrovascular
disease, different etiologies of dementia developed (utilizing recent
advances in pathological classiﬁcation), the nature and severity of
symptoms, in modulating the odds of developing dementia in
depressive elders.
We deduce from this systematic review that depressive
symptoms can be an independent risk factor for as well as a
prodromal manifestation of dementia. In some cases, they may
both stem from common risk factors such as cerebrovascular
disease. In others, they may not have causal connections at all
and simply occur together by chance—as two separate yet
prevalent neuropsychiatric diseases with overlapping and
prevalent risk factors. It remains, on the basis of these ﬁndings,
challenging to identify those depressed elders at an increased risk
of later dementia in clinical practice and, by extension, who
would beneﬁt from speciﬁc interventions to attenuate this risk.
Therefore, further research is needed to unravel the association
between depression and dementia. Preferentially, this research
should use a large database to have sufﬁcient statistical power to
determine which risk factors–possibly a combination of clinical
characteristics and biomarkers, hardly available at all in the studies
we examined—increase the risk of conversion to dementia in the
depressed elderly. These risk factors should subsequently be
validated in prospective, longitudinal clinical studies including
elders with and without depressive symptoms in whom clinical,
biochemical, and neuropsychological follow-up will decipher
which (sub)group later develops cognitive deterioration and
dementia. These risk factors can then be incorporated into a
clinically useful risk score, of paramount importance for future
efforts in the prevention of dementia—and therefore of interest to
clinicians, researchers, and patients worldwide.AUTHOR CONTRIBUTIONS
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